Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PAVmed Inc. - Common Stock (NQ:PAVM)

0.4298 +0.0073 (+1.73%)
Streaming Delayed Price Updated: 11:58 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PAVmed Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
From Lucid Diagnostics Inc.
Via Business Wire
44 Biggest Movers From Yesterday
Gainers Benessere Capital Acquisition Corp. (NASDAQ: BENER) shares jumped 66.5% to close at $0.4530 on Thursday. Grove, Inc. (NASDAQ: GRVI) gained 39.3% to close at $6.98 after... 
Via Benzinga
PAVM Stock: One Big Reason Why PAVmed Is Plunging Today
Today, a relatively disappointing start to trading for a PAVmed subsidiary, Lucid Diagnostics, is driving some bearish price action. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP... 
Via Benzinga
The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc... 
Via Benzinga
Lucid Diagnostics Announces Pricing of Initial Public Offering
From PAVmed Inc.
Via Business Wire
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
Via Benzinga
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
From PAVmed Inc.
Via Business Wire
PAVmed to Host Digital Health Virtual Investor Event
From PAVmed Inc.
Via Business Wire
58 Biggest Movers From Yesterday
Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares surged 73.4% to close at $12.80 on Thursday following news the company will buy ZACC Kabushiki Kaisha for $3.362... 
Via Benzinga
Why PAVmed Shares Are Trading Higher Today
PAVmed Inc (NASDAQ: PAVM) is trading higher Thursday after the company announced its majority-owned subsidiary, Lucid Diagnostics, filed a registration statement for a... 
Via Benzinga
These 2 Nasdaq Small Caps Just Got Big Boosts
In a rising market, these companies looked especially impressive. 
Via The Motley Fool
Topics Stocks
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers TransCode Therapeutics (NASDAQ:RNAZ) stock rose 94.3% to $5.09 during Thursday's regular session. TransCode Therapeutics's stock is trading at a volume of... 
Via Benzinga
PAVmed's Subsidiary, Lucid Diagnostics Files For $58M IPO
Lucid Diagnostic, a maker of diagnostic tests for esophageal precancer and cancer, filed to raise up to $58 million in an ... 
Via Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares jumped 101% to $14.87 following news the company will buy ZACC Kabushiki Kaisha for $3.362 million. TransCode... 
Via Benzinga
PAVmed Subsidiary, Lucid Diagnostics, Files Registration Statement for Proposed Initial Public Offering
From PAVmed, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 23.66% to $3.24 during Thursday's pre-market session. The company's market cap stands at $41.8... 
Via Benzinga
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Amplitude Healthcare Acquisition Corporation (NASDAQ: AMHC) rose 61.8% to $16.55 in pre-market trading. The company disclosed that shareholders approved the business... 
Via Benzinga
PAVmed Subsidiary Veris Health Joins Microsoft for Startups Global Program and Engages Loka as Software Development Partner
From PAVmed Inc.
Via Business Wire
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
PAVmed to Participate in September Investor and MedTech Conferences
From PAVmed Inc.
Via Business Wire
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Biolase (NASDAQ:BIOL) stock increased by 38.01% to $0.87 during Friday's regular session. Trading volume for this security as of 12:35 EST is 80.8 million,... 
Via Benzinga
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... 
Via Benzinga
Why Shares of PAVmed Were Down This Morning
Investors are growing impatient about a planned spinoff. 
Via The Motley Fool
PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results
From PAVmed Inc.
Via Business Wire
78 Biggest Movers From Friday
Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering. Flora Growth... 
Via Benzinga
53 Stocks Moving In Friday's Mid-Day Session
Gainers BIOLASE, Inc. (NASDAQ: BIOL) shares climbed 30.9% to $0.8270 after the company reported better-than-expected Q2 sales. The company said it continues to experience demand... 
Via Benzinga
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.